Karyopharm Therapeutics (KPTI) Assets Average (2013 - 2026)

Karyopharm Therapeutics (KPTI) has reported Assets Average for 14 consecutive years, with $109.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average fell 5.53% year-over-year to $109.9 million; the trailing twelve-month figure through Jun 2026 stood at $109.9 million (down 5.53% YoY), and the FY2025 full-year result was $136.4 million, down 32.61% from the prior year.
• Assets Average rose to $109.9 million in Q2 2026 per KPTI's latest filing, from $102.3 million in the prior quarter.
• Across five years, Assets Average topped out at $342.0 million in Q1 2023 and bottomed at $100.6 million in Q3 2025.
• Historically, Assets Average has averaged $217.2 million across 5 years, with a median of $222.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Assets Average rose 16.42% in 2023, then tumbled 50.15% in 2025.
• Over 5 years, Assets Average stood at $294.7 million in 2022, then fell by 13.4% to $255.2 million in 2023, then slumped by 30.66% to $176.9 million in 2024, then slumped by 42.17% to $102.3 million in 2025, then increased by 7.37% to $109.9 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $109.9 million, $102.3 million, and $100.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.